| Date | Title | Description |
| 27.03.2026 | eMed Secures $200M Funding, Valuation Surpasses $2 Billion, Targets Employer Healthcare Costs | eMed, a Miami-based digital healthcare innovator, recently secured $200 million in fresh funding. This substantial investment pushes its valuation beyond $2 billion. The capital infusion targets the firm's advanced agentic AI platform. It a... |
| 26.03.2026 | eMed Raises $200M in Funding | eMed, a Miami, FL-based digital healthcare company, raised $200M in funding, at over $2 Billion valuation.
The round was led by AON Consulting, with participation from Tom Brady (CWO), Jeff Aronin, Ara Cohen, Antonio Gracias, Joe Lonsdale, ... |
| 06.02.2026 | Science 37 Becomes First FDA-Inspected Site to Deliver Clinical Trials to Patients' Homes | Science 37 delivers clinical research trials directly to patients' homes.
Science 37 is a leading patient access company in clinical research that delivers trials directly to patients' homes.
We go directly to the patient’s home, providing ... |
| 09.05.2024 | 2024 MedTech Breakthrough Award Winners Announced | What You Should Know:
– MedTech Breakthrough, a market intelligence organization focused on healthcare technology, today revealed the winners of its prestigious 8th annual awards program.
– These awards recognize the most innovative and imp... |
| 09.04.2024 | Q1 2024 Digital Health Funding: A Reset & Refocus on Outcomes | What You Should Know:
– Q1 2024 Digital health funding in the U.S. reached $2.7B across 133 deals, with an average deal size of $20.6M, according to Rock Health’s Q1 2024 Digital Health Funding Report.
– The report reveals the digital healt... |
| 08.04.2024 | Healthtech investing still lags behind even as funding grew 42% in Q1 | Investments went up 42% from Q4 to $2.7B, but they're down 20% from the $3.4B in Q1 2023
2023 was a very rough year for healthtech investing: while Q1 was relatively healthy, growing 26% from the previous quarter, the rest of the year saw b... |
| 02.02.2023 | Science 37 Acquires Vault Health’s Life Sciences Platform To Bolster its Metasite Capabilities | Science 37 Holdings, the industry-leading Metasite, announced that it has acquired the life sciences platform from Vault Health, a national leader in remote diagnostics and COVID testing, to further enhance clinical trial workflow orchestra... |
| 02.02.2023 | Clinical trial company Science 37 buys life science assets from Vault Health | Photo: Martin Barraud/Getty Images |
| 02.02.2023 | Clinical trial company Science 37 buys life sciences platform from Vault Health | The company says the purchase will accelerate its development plans for workflow features
When it comes to clinical trials, there are a number of factors that can stand in the way of someone participating, including travel time, costs, geog... |
| 19.10.2022 | Decentralization in Action: What Oncology Trials Look Like Now, Upcoming Webinar Hosted by Xtalks | Oncology trials have especially benefited with DCT practices.
TORONTO (PRWEB) October 19, 2022
The adoption of decentralized and agile clinical trials has increased exponentially over the past few years. As adoption accelerates, so do the p... |
| 13.09.2022 | How Agile Clinical Trials Unlock Universal Access to Rare Disease Research, Upcoming Webinar Hosted by Xtalks | Science 37’s research shows that rare diseases will be among the most prevalent categories for incorporating decentralized approaches into future clinical trial designs.
TORONTO (PRWEB) September 13, 2022
The agile clinical trial of the fut... |
| 02.05.2022 | Oncology Clinical Trial Access — Increasing Participation of Women in Clinical Trials, Upcoming Webinar Hosted by Xtalks | Research suggests that social determinants of health, poverty, physician bias, patient study burden and access challenges, are factors leading to fewer women participating in cancer trials.
TORONTO (PRWEB) May 02, 2022
There are low numbers... |
| 13.01.2022 | Science 37 : reg; to Become Publicly Listed via Merger… | Transaction values Science 37 at an enterprise value of approximately $1.05 billion at closing
Positions Science 37 with a balance sheet of up to $250 millionto fund its decentralized trial technology platform, extend into new adjacencies, ... |
| 17.11.2021 | Science 37 : reg; Reports Quarterly Financial Results for the Period Ended September 30, 2021 | November 15
Science 37 Holdings, Inc. (Nasdaq: SNCE) today reported its financial results for the quarter ended September 30, 2021
LOS ANGELES, November 15, 2021 - Science 37 Holdings, Inc. (Nasdaq: SNCE), ("Science 37") the Opera... |
| 15.11.2021 | Science 37 : Reports Quarterly Financial Results for the Period Ended September 30, 2021 - Form 8-K | Science 37 Reports Quarterly Financial Results for the Period Ended September 30, 2021
LOS ANGELES, November 15, 2021 - Science 37 Holdings, Inc. (Nasdaq: SNCE), ("Science 37") the Operating System for today's more agile clinical ... |
| 22.10.2021 | Veta Health Apoints CEO, Walgreens Leadership Appointments, Walmart’s New VP, Other Executive Appointments | James Sutcliffe, CEO at Veta Health
Veta Health, a global provider of digital solutions for remote patient care and chronic condition monitoring appoints James Sutcliffe as Chief Executive Officer. Sutcliffe will guide the strategic directi... |
| 14.10.2021 | Lifesci Acquisition II : Science 37, the Operating System for Agile Clinical Trials, Closes Business Combination with LifeSci Acquisition II Corp. and Will Begin Trading on Nasdaq as SNCE - Form 8-K | Science 37, the Operating System for Agile Clinical Trials, Closes Business Combination with LifeSci Acquisition II Corp. and Will Begin Trading on Nasdaq as SNCE
● Science 37 to debut on Nasdaq as a publicly traded company under ticker sym... |
| 07.10.2021 | LifeSci Acquisition II : Science 37, the Operating System for Agile Clinical Trials, Closes Business Combination with LifeSci Acquisition II Corp. and Will Begin Trading on Nasdaq as SNCE | Science 37 to debut on Nasdaq as a publicly traded company under ticker symbol “SNCE”
Business combination will provide Science 37 with approximately $235 million in cash proceeds to support continued growth
Science 37 to fuel its mission t... |
| 07.10.2021 | Science 37 Closes Business Combination with LifeSci Acquisition II Corp. and Begin Trading on Nasdaq | Science 37, Inc., a Los Angeles, California-based provider of an Operating System for today’s agile clinical trials, completed its previously announced business combination with LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a blank check com... |
| 07.05.2021 | LifeSci Acquisition II : Positions Science 37 with a balance sheet of up to $250 million to fund its decentralized trial technology platform, extend into new adjacencies, and power the next generation... | Positions Science 37 with a balance sheet of up to $250 million to fund its decentralized trial technology platform, extend into new adjacencies, and power the next generation in clinical research
· $80 million via LifeSci Acquisition II Co... |
| 07.05.2021 | Science 37 Becomes Publicly Listed via SPAC | Science 37, Inc., the Los Angeles, CA-based developer of the Decentralized Clinical Trial Operating System™, and LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a blank check company targeting the biopharma, medical technology, digital health ... |
| 07.05.2021 | Clinical trial platform Science 37 is going public via a SPAC merger | The transaction will value the company at $1.05 billion
One of big trends of 2021 has been the emergence of special-purpose acquisition companies. or SPACs, which act as an alternative way for companies to enter the public market without ne... |
| 29.03.2021 | SYNEOS HEALTH, INC.
Syneos Health Partners with Science 37® to Transform Clinical Trials – Increasing Speed and Diversity | MORRISVILLE, N.C. and LOS ANGELES, March 29, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Science 37, the industry’s only Decentralized Clinical Trial Operati... |
| 15.02.2021 | Decentralized Trials for Rare Diseases: Bringing Research to the Patient, Upcoming Webinar Hosted by Xtalks | As we look ahead at continuing research in the post-pandemic era, a hybrid model leveraging patient-friendly technology and remote study visits will surely emerge.
TORONTO (PRWEB) February 15, 2021
Clinical trials for rare diseases have alw... |
| 26.01.2021 | Strategies that will help make 2021 a banner year for life sciences industries | Pharma 4.0 is here to stay
As pharmaceutical executives continue to grapple with an ever-increasing array of complexities, costs and regulations associated with operations, a greater number of them are turning to Pharma 4.0 manufacturing as... |
| 21.01.2021 | Science 37® Launches 'Science 37 Certified'--a Partnership Program Enabling CROs to Effectively Execute Decentralized Clinical Trials | |
| 10.09.2020 | Science 37® Launches Integrated Electronic Health Records into Its Industry-Leading Decentralized Clinical Trial Technology Platform | |
| 21.08.2020 | Pharma giants back a leader in virtual clinical trials as Covid-19 blights sites | While traditional trial sites are under enormous pressure amid the Covid-19 pandemic, 3 pharma giants continue to back a leader in virtual clinical trials.
Los Angeles-based Science 37 closed a $40 million funding rou... |
| 21.08.2020 | StartUPDATES: New developments from healthcare startups | The SmartExam platform works like a virtual assistant to the provider, by guiding patients through a dynamic, online medical interview and sending the collected information and the patient’s medical history to a reviewing provider. The clin... |
| 20.08.2020 | Science 37 Raises $40M in Funding | Science 37, a Los Angeles, CA-based provider of decentralized clinical trials, closed a $40m funding round.
The round was led by existing investors Lux Capital, Redmile Group, and PPD, Inc. (Nasdaq: PPD), joined by existing investors Novart... |
| 20.08.2020 | Clinical Trials at Home? Science 37's Answer to Pharma's Problem | Convincing people to take part in life-saving clinical drug trials was difficult even before the pandemic. But the coronavirus halted efforts by many drugmakers, as hospitals and research facilities closed or channeled their resources to CO... |
| 20.08.2020 | Science 37® Raises $40 Million to Extend Its Leadership in the Decentralized Clinical Trial Market | |
| 03.02.2020 | UK invests £65 million in international science projects hosted by Fermilab | UK invests £65 million in international science projects hosted by Fermilab
03-02-2020
Representatives from UK Research and Innovation and the US Department of Energy have signed an agreement that outlines £65 million worth of contributions... |
| 31.05.2018 | Check out who joined StartUp Health Academy’s latest cohort | Here’s an overview of the businesses based in part on StartUp Health’s blog post, info from the companies’ websites.
Advice Coach is a physical therapy business that helps patients recover from home. It produces a set of videos by the patie... |
| 26.03.2018 | This is how AI will shape drug discovery | An oft-quoted statistic is that it takes 12 years and almost $2 billion dollars to bring an average drug to market. That is the raison d’être for the biotech VC industry, which saw $10 billion of capital invested in startups in 2017 alone, ... |
| 09.01.2018 | B Capital Group Partner: Pharma value chain will be area of interest for investors in 2018 | The Trump tax reform provisions offer some incentives for biopharma companies that add to the positive outlook, Teo noted. The repatriation tax and the lowered corporate tax rate are designed to incentivize corporations, including life scie... |
| 26.10.2017 | Bracket acquisition underscores the push to make clinical trials more flexible for patients | Adam Butler, Bracket strategic development and corporate marketing officer, said in an email that mProve has been a BYOD device pioneer and has a track record of working with pharma and regulators to make BYOD work in clinical trials.
Also ... |
| 25.04.2017 | GV Joins $29M Series C for Science 37 | PLAYA VISTA, Calif.--(BUSINESS WIRE)--Science 37, a trailblazing company focused on “site-less” clinical trials, announced today $29 million in Series C funding led by Glynn Capital Management with participation from GV. The round included ... |
| 25.04.2017 |
Science 37 Gets $29M To Extend Clinical Trials To Patient Homes
| Playa Vista-based Science 37, which is developing technology and a model that allows pharmaceuticals companies and others to conduct clinical trials in patients' homes--rather than dedicated, off-site facilities--has raised $29M in a Series... |
| 25.04.2017 | Science 37 Raises $29M in Funding | Science 37, a Playa Vista, Calif.-based company focused on site-less clinical trials, raised $29m in Series C funding.
The round was led by Glynn Capital Management with participation from GV, Amgen Ventures, as well as participation from a... |
| 25.04.2017 | Science 37 picks up $29 million more for remote clinical trials | Remote clinical trial company Science 37 has raised $29 million in a round led by Glynn Capital Management with participation from Google's investment arm GV. One more new investor -- AmGen ventures -- contributed, as did existing investors... |
| 25.04.2017 | GV joins $29 million investment into Science 37 to bring clinical trials to the home | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
Clinical trial technology company Science 37 has ... |
| 25.04.2017 | GV joins $29 million investment into Science 37 to bring clinical trials to the home | Clinical trial technology company Science 37 has raised $29 million in a Series C round of funding led by Glynn Capital Management, with participation from Alphabet’s investment arm (GV), Amgen Ventures, Lux Capital, Redmile Group, DRX Capi... |
| 25.04.2017 | Science 37 raises a $29M Series C for “site-less” clinical trials | “We basically started with the question: ‘What’s best for patients?’” explained cofounder and CEO Noah Craft in a phone interview.
The answer has evolved over the last two and a half years to include an end-to-end “site-less” solution for c... |
| 25.04.2017 | Science37 aims to democratize clinical research with a fresh $29 million in growth funding | Virtual clinical trials have come into their own thanks to widespread technology enabling patients of every background to input their experiences at the tap of a button. Science37 capitalizes on that trend by providing qualified patients fr... |
| 28.02.2017 | Lux Capital announces fresh $400 million fund to back ‘contrarians and outsiders’ from science and tech | Lux Capital, a venture capital (VC) firm that makes “long-term bets on contrarians and outsiders,” has announced a new $400 million fund, bringing its total currently under management to $1.1 billion.
With hubs in Menlo Park and New York Ci... |
| 28.02.2017 | Lux Capital announces fresh $400 million fund to back ‘contrarians and outsiders’ from science and tech | Did you miss a session from GamesBeat Summit 2022? All sessions are available to stream now. Learn more.
Lux Capital, a venture capital (VC) firm that makes “long-term bets on contrarians and outsiders,” has announced a new $400 million fun... |
| 19.01.2017 | What Pharma must do to win in Trump era | While Trump strongly criticized the pharmaceutical industry for both not manufacturing in the U.S. and high prices in his press conference, his position up to this point has been focused on pricing and not manufacturing. His Healthcare Refo... |
| 23.12.2016 | Is the direct-to-patient model the future of clinical trials? | While this disintermediation is highly disruptive to existing players, the benefits to the consumer are significant in terms of cost saving, convenience, and potentially new offerings. However, the existing players often adjust to the new m... |
| 18.10.2016 | Science 37 raises $31 million to bring clinical trials to the home | Clinical trial technology company Science 37 has raised $31 million in a series B round led by Redmile Group, with participation from Lux Capital, dRx Capital, and Sanofi-Genzyme BioVentures.
Founded out of Los Angeles in 2014, Science 37 i... |
| 18.10.2016 | Science 37 raises $31M from Sanofi, others for mobile clinical trials offering | Mobile clinical trials company Science 37, which connects willing individuals to researchers so they can participate in trials from their homes, has raised $31 million in Series B funding. Previously, the company raised $6.5 million.
The ro... |
| 18.10.2016 | Science 37 Raises $31M to Expand Virtual Clinical Trail Model | Science 37, Inc., a LosAngeles-based mobile technology and clinical trial startup that focuses on the development of networked patient-centric models for clinical research has raised $31 million in Series B funding led by Redmile Group. The... |
| 18.10.2016 | Science 37 Completes $6.5M Series A Financing | Science 37, a Los Angeles, CA-based based technology-enabled clinical research company, completed a $6.5m Series A financing.
The round was co-led by Lux Capital and dRx Capital.
The company intends to use the funds to accelerate developmen... |
| 21.11.2015 | Take a memo, Andreessen Horowitz: 4 areas where it should consider investments | Other investments include Benchling, which develops collaborative tools for life science research, Glow, an ovulation tracking app developer, and Omada Health.
It also invested in Massive Health, a company founded in 2010 that helped diabet... |
| 20.10.2015 |
Science 37 Raises $6.5M
| Los Angeles-based Science 37, a provider of technology-enabled, clinical research services, has raised $6.5M in a Series A funding round. The funding was co-led by Lux Capital and dRx Capital. Science37, which is led by CEO Noah Craft, says... |
| 20.10.2015 | Clinical trial platform uses telemedicine, mobile tech to improve access, cut costs | “It’s a totally new type of operating model,” Craft said in a phone interview. “We use a nice, easy interface that allows patients access from home and they can reach the principal investigator. From the patient perspective, the technology ... |
| 20.10.2015 | Science 37 Completes $6.5M Series A Financing | Science 37, a Los Angeles based technology-enabled clinical research company, completed a $6.5m Series A financing.
The round was co-led by Lux Ventures IV, L.P., a $350m fund targeting early-stage science and technology ventures, and the n... |
| 24.03.2011 | Science in the East gets a £70m boost from the Chancellor | Science in the East gets a £70m boost from the Chancellor
24-03-2011
Science in the East of England received a boost from the Chancellor in the Budget yesterday (Weds), when he announced that two East Anglian research facilities are to bene... |
| - | Take a memo, Andreessen Horowitz: 4 areas where it should consider investments | This week, Andreessen Horowitz said it’s launching a fund dedicated to investments in bioinformatics and “beyond the pill” technology. The venture capital firm had already gotten its feet wet with investments in these areas, but a dedicated... |
| - | Check out who joined StartUp Health Academy’s latest cohort | StartUp Health has added ten companies in the latest Academy cohort. The digital health companies include a remote monitoring service for physical therapy, a healthcare matchmaking program that connects patients based in China with U.S.-bas... |
| - | StartUPDATES: New developments from healthcare startups | With an eye toward expanding patient access and growing market share while using existing clinical resources, Genesis Health System has selected Bright.md’s SmartExam to power this new telehealth offering. Patients in the bi-state region of... |
| - | What Pharma must do to win in Trump era | “Getting away with murder” is a harsh condemnation of an industry dedicated to improving and saving lives, but that is what President-elect Donald Trump said of the pharmaceutical industry at his first post-election news conference earlier ... |
| - | Is the direct-to-patient model the future of clinical trials? | Black Friday, the day after Thanksgiving, is the biggest shopping day of the year in America. According to US News and World Reports, this year 99.1 million Americans shopped at malls and stores. However, an even larger number – 108 million... |
| - | Clinical trial platform uses telemedicine, mobile tech to improve access, cut costs | Science37, so named because 37C is the normal temperature of the human body, has raised a $6.5 million Series A round from dRx Capital –a joint venture between Qualcomm and Novartis, and Lux Capital‘s $350 million venture fund Lux Ventures ... |
| - | Science 37 raises a $29M Series C for “site-less” clinical trials | Science 37 cofounders Belinda Tan and Noah Craft
If you’re not quite sure what healthcare “convergence” truly means and achieves, take a look at Science 37.
Based in Playa Vista, California, the company operates at the intersection of four ... |
| - | Bracket acquisition underscores the push to make clinical trials more flexible for patients | The patient-centered clinical trial has been a favorite turn of phrase for the pharma and contract research organization industry in the past few years. But the adoption of technologies that allow scientists to build in more flexibility int... |
| - | This is how AI will shape drug discovery | As healthcare venture capitalists, we specialize in technologies that have the potential to transform large markets in healthcare. Earlier this year, we predicted that 2018 would be a year of venture and M&A activity across the pharma v... |
| - | B Capital Group Partner: Pharma value chain will be area of interest for investors in 2018 | At the intersection of the drug price debate and tax reform, B Capital Group Partner Gavin Teo sees technologies that can bring drugs to market faster as a significant area of investor interest this year. The Trump administration’s tax refo... |
| - | Startups taking new approaches to clinical trials have netted $1.6 billion from investors. Meet the top 10 upstarts trying to bring drug research into the 21st century. | A medical technician handles coronavirus tests at the microbiology laboratory of Naples. Salvatore Laporta/Kontrolab/Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Coronavir... |
| - | Strategies that will help make 2021 a banner year for life sciences industries | Under normal circumstances, the life sciences industry, while innovative, is weighed down by standard operating procedures, regulations and old habits that make it slow, inefficient and expensive. But in 2020, the life sciences industry has... |
